In this perspective review, the role Hematopoietic Progenitor Kinase 1 (HPK1) in tumor immunity will be reviewed, with special emphasis on how T cells are negatively-regulated at different junctures of cancer-immunity cycle by this regulatory kinase. The review will highlight the strengths and weaknesses of HPK1 as a candidate target for novel immuno-oncology (IO) drug development that is centered on the use of small molecule kinase inhibitor to modulate the immune response against cancer. Such a therapeutic approach, if proven successful, could supplement the cancer cell-centric standard of care therapies in order to fully meet the therapeutic needs of cancer patients.

Original languageEnglish
Article numbere55122
Pages (from-to)1-15
Number of pages15
StatePublished - Sep 2020


Dive into the research topics of 'A perspective on hpk1 as a novel immuno-oncology drug target'. Together they form a unique fingerprint.

Cite this